Archives

Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

B Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101,… Login to continue reading Login…

Read MoreAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

Full-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities

B SUZHOU, China and GEMBLOUX, Belgium, May 18, 2026 /PRNewswire/ — Full-Life Technologies (“Full-Life“, the “Company“), a fully-integrated global radiotherapeutics company, today announced the completion… Login to continue reading Login…

Read MoreFull-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities